**Supplementary Table 2** Comparison of baseline demographic and clinical characteristics among participants with SARS-CoV-2 infection who agreed and declined to be contacted for future studies<sup>1,2,3,4</sup>

<u>otaaloo</u>	Agreed to be Contacted for Future Studies (n = 11,924)	Declined to be Contacted for Future Studies (n = 3,554)
Gender	( , = .)	(** ***)
Cisgender man Cisgender woman Transgender man Transgender woman Different identity Missing	1,829 (15%) 9,934 (83%) 15 (0.1%) 11 (0.1%) 127 (1.1%) 8	510 (14%) 2,992 (84%) 6 (0.2%) 1 (<0.1%) 36 (1.0%)
Race White Black Other Mixed race Missing	10,538 (89%) 348 (2.9%) 563 (4.8%) 384 (3.3%) 91	3,067 (88%) 88 (2.5%) 213 (6.1%) 117 (3.4%) 69
Hispanic, Latino or Spanish origin Missing	892 (7.5%) 68	289 (8.2%) 35
Median age, IQR Missing	46 (36,57) 34	42 (33,52) 6
Educational attainment High school, GED, or less Some college, Associates/technical degree Bachelor's degree Post-graduate degree Missing	620 (5.2%) 3,009 (25%) 3,601 (30%) 4,676 (39%) 18	243 (6.9%) 823 (23%) 1,116 (32%) 1,356 (38%) 16
Annual household income <\$25,000 \$25,000 - \$34,999 \$35,000 - \$49,999 \$50,000 - \$74,999 \$75,000 or greater Missing	1,163 (11%) 712 (6.5%) 1,125 (10%) 2,084 (19%) 5,939 (54%) 901	394 (13%) 227 (7.4%) 328 (11%) 576 (19%) 1,540 (50%) 489
Region Northeast Midwest South West Missing	2,216 (19%) 2,383 (20%) 4,790 (40%) 2,522 (21%) 13	679 (19%) 810 (23%) 1,290 (36%) 766 (22%) 9
Hospitalization status at initial COVID-19 illness Not hospitalized Hospitalized Missing	10,612 (89%) 1,304 (11%) 8	3,305 (93%) 245 (6.9%) 4
Comorbid conditions Diabetes Cardiovascular disease/congestive heart failure Hypertension Chronic kidney disease Cancer Asthma/reactive airway disease/chronic lung disease	561 (4.7%) 287 (2.4%) 1,930 (16%) 97 (0.8%) 306 (2.6%) 2,077 (17%)	119 (3.4%) 68 (1.9%) 492 (14%) 32 (0.9%) 71 (2.0%) 485 (14%)

**Supplementary Table 2** Comparison of baseline demographic and clinical characteristics among participants with SARS-CoV-2 infection who agreed and declined to be contacted for future studies<sup>1,2,3,4</sup>

	Agreed to be Contacted for Future Studies (n = 11,924)	Declined to be Contacted for Future Studies (n = 3,554)
Overweight/obese	3,670 (31%)	969 (27%)
Autoimmune disorder	1,203 (10%)	297 (8.4%)
Stroke	93 (0.8%)	14 (0.4%)
Depression/anxiety/other mental health condition	4,262 (36%)	1,171 (33%)
Missing	1	0
Long COVID status at survey completion		
Has long COVID	7,698 (65%)	2,069 (58%)
Does not have long COVID	693 (5.8%)	421 (12%)
Cannot be determined4	3,533 (30%)	1,064 (30%)

<sup>&</sup>lt;sup>1</sup>Missing data were due to invalid data, "don't know" responses, "refuse to answer" responses, and missing responses. Percentages do not add up to 100% due to missing data. The number of missing data varies due to participants dropping out of the survey at different sections.

<sup>&</sup>lt;sup>2</sup>Baseline data in participants with a history of SARS-CoV-2 infection is as of October 20, 2022.

<sup>&</sup>lt;sup>3</sup>Limited to participants with a defined long COVID status. Long COVID status was determined using the WHO definition. 320 participants without a defined long COVID status were excluded: 283 provided an initial SARS-CoV-2 infection date before the first confirmed positive test in the United States (January 20, 2020), 28 provided an invalid SARS-CoV-2 infection date, nine did not provide a SARS-CoV-2 infection date nor report experiencing symptoms of COVID-19.

<sup>&</sup>lt;sup>4</sup>Long COVID status could not be determined because fewer than 12 weeks existed between initial SARS-CoV-2 infection and survey completion.